Chiesi announces departure of Ugo Di Francesco as CEO

5 September 2022

A new chapter opens at privately-held Italian drugmaker Chiesi Farmaceutici as the 11-year tenure of chief executive Ugo Di Francesco, aged 62, comes to a close at the end of 2022.

Chiesi says it has begun a search for its next-generation CEO to take over the baton and build on the legacy.

“The journey that Ugo mapped out for the business, during what was undoubtedly a decade of change, is an exciting one. Chiesi has consolidated extraordinary growth and a solid future thanks to the joint efforts and contribution of the family, the CEO and the management team. We are now actively looking for a new leader who will be able to take his foundation and use it to continue building an ambitious future for all our people and patients,” said Chiesi president Alberto Chiesi, who also highlighted how the group’s family values will guarantee a seamless leadership transition.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK